Article
EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation.
PloS one - 1 Jan 2013
Yamada Teppei, Azuma Koichi, Muta Emi, Kim Jintaek, Sugawara Shunichi, Zhang Guang Lan, Matsueda Satoko, Kasama-Kawaguchi Yuri, Yamashita Yuichi, Yamashita Takuto, Nishio Kazuto, Itoh Kyogo, Hoshino Tomoaki, Sasada Tetsuro
Abstract excerpt
Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, has achieved high clinical response rates in patients with non-small cell lung cancers (NSCLCs). However, over time, most tumors develop acquired resistance to EGFR-TKIs, which is associated with the secondary EGFR T790M resistance mutation in about half the cases. Currently there are no...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.